Changes in choline metabolism as potential biomarkers of phospholipase Cγ1 inhibition in human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1305-1311

  Beloueche Babari, Mounia ^a,b   Peak, Joanna C ^a   Jackson, L Elizabeth ^a   Tiet, May Yung ^a   Leach, Martin O ^a   Eccles, Suzanne A ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PHOSPHOLIPASE C GAMMA1; PHOSPHOLIPASE C GAMMA2; PHOSPHORYLCHOLINE; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA;

ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; PHOSPHOLIPASE C GAMMA; PHOSPHORYLCHOLINE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 66849138226     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0039     Document Type: Article

References (56)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
2. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31-101.
3. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-695 (Pubitemid 44781029)
4. Jones NP, Peak J, Brader S, Eccles SA, Katan M. PLCγ1 is essential for early events in integrin signalling required for cell motility. J Cell Sci 2005;118:2695-2706 (Pubitemid 40932894)
5. Matsumoto T, Mugishima H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb 2006;13:130-135
6. Wells A, Grandis JR. Phospholipase C-γ1 in tumor progression. Clin Exp Metastasis 2003;20:285-290
7. Wells A, Ware MF, Allen FD, Lauffenburger DA. Shaping up for shipping out: PLCγ signaling of morphology changes in EGF-stimulated fibroblast migration. Cell Motil Cytoskeleton 1999;44:227-233
8. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-1973 (Pubitemid 30158664)
9. Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 2000;105:9-13. (Pubitemid 30036381)
10. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001;264:29-41. (Pubitemid 32989079)
11. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008;27:5443-5453
12. Park JG, Lee YH, Kim SS, et al. Overexpression of phospholipase C-γ1 in familial adenomatous polyposis. Cancer Res 1994;54:2240-2244 (Pubitemid 24138702)
13. Eccles SA. Targeting key steps in metastatic tumour progression. Curr Opin Genet Dev 2005;15:77-86. (Pubitemid 40127635)
14. Shepard CR, Kassis J, Whaley DL, Kim HG, Wells A. PLCγ contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 2007;26:3020-3026 (Pubitemid 46733649)
15. Sala G, Dituri F, Raimondi C, et al. Phospholipase Cγ1 is required for metastasis development and progression. Cancer Res 2008;68:10187-10196
16. Homma MK, Homma Y, Yamasaki M, Ohmi-Imajoh S, Yuasa Y. Growth inhibition by phospholipase C inhibitor peptides of colorectal carcinoma cells derived from familial adenomatous polyposis. Cell Growth Differ 1996;7:281-288 (Pubitemid 26360767)
17. Lee YH, Kim S, Kim J, et al. Overexpression of phospholipase C-γ1 suppresses UVC-induced apoptosis through inhibition of c-fos accumulation and c-Jun N-terminal kinase activation in PC12 cells. Biochim Biophys Acta 1999;1440:235-243 (Pubitemid 29424188)
18. Nozawa H, Howell G, Suzuki S, et al. Combined inhibition of PLCγ-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 2008;14:4336-4344
19. Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002;38:2189-2193 (Pubitemid 35223253)
20. Workman P. How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
21. Workman P, Aboagye EO, Chung YL, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 2006;98:580-598 (Pubitemid 43904842)
22. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-324
23. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413-439 (Pubitemid 30016999)
24. 31P MRS of experimental tumours. NMR Biomed 1993;6:345-365
25. 31P measurements of response to treatment. NMR Biomed 1998;11:314-340
26. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn 2006;6:821-829 (Pubitemid 44903998)
27. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharmacol 2006;3:496-506. (Pubitemid 44639126)
28. Serkova NJ, Spratlin JL, Eckhardt SG. NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther 2007;9:572-585 (Pubitemid 350179097)
29. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 2007;104:249-255
30. Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005;65:9369-9376 (Pubitemid 41508005)
31. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996;16:1375-1379
32. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002;62:1966-1970 (Pubitemid 34408439)
33. Glunde K, Jie C, Bhujwalla ZM.Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-4276 (Pubitemid 38802433)
34. Larrodera P, Cornet ME, Az-Meco MT, et al. Phospholipase C-mediated hydrolysis of phosphatidylcholine is an important step in PDGF-stimulated DNA synthesis. Cell 1990;61:1113-1120 (Pubitemid 20203493)
35. Cai H, Erhardt P, Szeberenyi J, et al. Hydrolysis of phosphatidylcholine is stimulated by Ras proteins duringm itogenic signal transduction. Mol Cell Biol 1992;12:5329-5335
36. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993;8:2959-2968 (Pubitemid 23312899)
37. Jimenez B, Del PL, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 1995;57:141-149
38. Bhujwalla ZM, Aboagye EO, Gillies RJ, et al. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med 1999;41:897-903. (Pubitemid 29211131)
39. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001;84:691-696 (Pubitemid 32239005)
40. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res 2005;65:3356-3363 (Pubitemid 40524620)
41. Beloueche-Babari M, Jackson LE, Al-Saffar NM, et al. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther 2006;5:187-196
42. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004;10:6661-6668 (Pubitemid 39346563)
43. Chung YL, Troy H, Banerji U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003;95:1624-1633 (Pubitemid 37455930)
44. Chung YL, Troy H, Kristeleit R, et al. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 2008;10:303-313
45. Sankaranarayanapillai M, Tong WP, Maxwell DS, et al. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol Cancer Ther 2006;5:1325-1334 (Pubitemid 43881326)
46. Peak JC, Jones NP, Hobbs S, Katan M, Eccles SA. Phospholipase Cγ1 regulates the Rap GEF1-1 signalling axis in the control of human prostate carcinoma cell adhesion. Oncogene 2008;27:2823-2832
47. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5:522-532
48. Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG, Wells A. A role for phospholipase C-γ-mediated signaling in tumor cell invasion. Clin Cancer Res 1999;5:2251-2260 (Pubitemid 29399285)
49. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-84 (Pubitemid 29062961)
50. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-3603 (Pubitemid 32694969)
51. 1H-NMR metabolic markers of malignancy correlate with spontaneous metastases in a murine mammary tumor model. Int J Oncol 2005;27:257-263
52. Ackerstaff E, Gimi B, Artemov D, Bhujwalla ZM. Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia 2007;9:222-235 (Pubitemid 46457239)
53. Glunde K, Jie C, Bhujwalla ZM. Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia 2006;8:758-771 (Pubitemid 44465527)
54. Ledeen RW, Wu G. Nuclear sphingolipids: metabolism and signaling. J Lipid Res 2008;49:1176-1186
55. Schwarzer N, Nost R, Seybold J, et al. Two distinct phospholipases C of Listeria monocytogenes induce ceramide generation, nuclear factor-κB activation, and E-selectin expression in human endothelial cells. J Immunol 1998;161:3010-3018 (Pubitemid 28425726)
56. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002;21:937-946 (Pubitemid 34146307)